Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

The NR2B subunit-selective NMDA receptor antagonist, CP-101,606 reduces pain intensity in patients with central and peripheral neuropathic pain

The NR2B subunit-selective NMDA receptor antagonist, CP-101,606 reduces pain intensity in patients with central and peripheral neuropathic pain. Society for Neuroscience. 2003.


© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.